Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] jumped around 0.64 points on Monday, while shares priced at $2.81 at the close of the session, up 29.49%. The company report on March 11, 2024 at 7:15 AM that Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update.
Commercial launch of INPEFA® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Patient enrollment underway in PROGRESS, a Phase 2b study of LX9211 in Diabetic Peripheral Neuropathic Pain; topline data anticipated Q2 2025.
Compared to the average trading volume of 3.95M shares, LXRX reached a trading volume of 29412887 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Lexicon Pharmaceuticals Inc [LXRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXRX shares is $5.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Lexicon Pharmaceuticals Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on March 07, 2023. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on August 12, 2022, representing the official price target for Lexicon Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $7, while JP Morgan analysts kept a Neutral rating on LXRX stock. On January 29, 2021, analysts increased their price target for LXRX shares from 2 to 8.
The Average True Range (ATR) for Lexicon Pharmaceuticals Inc is set at 0.29, with the Price to Sales ratio for LXRX stock in the period of the last 12 months amounting to 568.80. The Price to Book ratio for the last quarter was 4.95, with the Price to Cash per share for the same quarter was set at 0.69.
How has LXRX stock performed recently?
Lexicon Pharmaceuticals Inc [LXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 27.15. With this latest performance, LXRX shares gained by 22.17% in over the last four-week period, additionally plugging by 76.73% over the last 6 months – not to mention a rise of 24.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LXRX stock in for the last two-week period is set at 60.68, with the RSI for the last a single of trading hit 63.89, and the three-weeks RSI is set at 59.90 for Lexicon Pharmaceuticals Inc [LXRX]. The present Moving Average for the last 50 days of trading for this stock 2.07, while it was recorded at 2.31 for the last single week of trading, and 1.77 for the last 200 days.
Lexicon Pharmaceuticals Inc [LXRX]: Deeper insight into the fundamentals
Lexicon Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.91 and a Current Ratio set at 6.92.
Earnings analysis for Lexicon Pharmaceuticals Inc [LXRX]
With the latest financial reports released by the company, Lexicon Pharmaceuticals Inc posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -23.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXRX.
Insider trade positions for Lexicon Pharmaceuticals Inc [LXRX]
The top three institutional holders of LXRX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in LXRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in LXRX stock with ownership which is approximately 5.8325%.
